Successsful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient

被引：63

作者：

Consigny, S

Dhedin, N

Datry, A

Choquet, S

Leblond, V

Chosidow, O

机构：

[1] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Internal Med, Paris, France

[2] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Hematol, Paris, France

[3] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Parasitol Mycol, Paris, France

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 37卷 / 02期

关键词：

D O I：

10.1086/375842

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voriconazole might be an alternative therapy for patients with neutropenia who have fusariosis that is refractory or unresponsive to amphotericin B or its liposomal formulation.

引用

页码：311 / 313

页数：3

共 19 条

[1] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
Ally, R
Schürmann, D
Kreisel, W
Carosi, G
Aguirrebengoa, K
Dupont, B
Hodges, M
Troke, P
Romero, AJ
[J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) : 1447 - 1454
[2] Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management
Boutati, EI
Anaissie, EJ
[J]. BLOOD, 1997, 90 (03) : 999 - 1008
[3] Voriconazole: A second-generation triazole
Chandrasekar, PH
Manavathu, E
[J]. DRUGS OF TODAY, 2001, 37 (02) : 135 - 148
[4] The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis
Clancy, CJ
Nguyen, MH
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (01) : 127 - 130
[5] Clancy CJ, 1998, EUR J CLIN MICROBIOL, V17, P573
[6] In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
Espinel-Ingroff, A
Boyle, K
Sheehan, DJ
[J]. MYCOPATHOLOGIA, 2001, 150 (03) : 101 - 115
[7] Ghannoum MA, 2002, EUR J MED RES, V7, P242
[8] In vitro and in vivo experimental activities of antifungal agents against Fusarium solani
Guarro, J
Pujol, I
Mayayo, E
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) : 1256 - 1257
[9] Hennequin C, 1997, J MED VET MYCOL, V35, P107
[10] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
Herbrecht, R
Denning, DW
Patterson, TF
Bennett, JE
Greene, RE
Oestmann, JW
Kern, WV
Marr, KA
Ribaud, P
Lortholary, O
Sylvester, R
Rubin, RH
Wingard, JR
Stark, P
Durand, C
Caillot, D
Thiel, E
Chandrasekar, PH
Hodges, MR
Schlamm, HT
Troke, PF
de Pauw, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) : 408 - 415

← 1 2 →